TREA

90647320 - BEIGENE

Follow

Information

  • Trademark
  • 90647320
  • Serial Number
    90647320
  • Registration Number
    6860858
  • Filing Date
    April 15, 2021
    3 years ago
  • Registration Date
    September 27, 2022
    2 years ago
  • Transaction Date
    March 27, 2023
    a year ago
  • Status Date
    September 27, 2022
    2 years ago
  • Published for Opposition Date
    October 19, 2021
    3 years ago
  • Location Date
    August 22, 2022
    2 years ago
  • First Use Anywhere Date
    September 20, 2021
    3 years ago
  • First Use In Commerce Date
    September 20, 2021
    3 years ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    KETCHUM, BRENDAN J
  • Attorney Docket Number
    140679539553
    Attorney Name
    Kristen S. Ruisi
    Law Office Assigned Location Code
    N70
  • Owners
Information
Mark Drawing Code
3000
Mark Identification
BEIGENE
Case File Statements
  • GS0401: Custom manufacturing services in the nature of chemical processing and production of medicines and pharmaceuticals for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases
  • DM0000: The mark consists of a shaded square in red with a stylized red square and a star cutout in the center of the stylized square to the left of the black wording "BeiGene" with a red arrow as part of the letter "G.
  • GS0051: Pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemico-pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; drugs in the nature of pharmaceutical preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biological preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for pharmaceutical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; medicines for human purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; Injectable pharmaceuticals for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; crude drugs in the nature of pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; Biochemical preparations for medical use for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases
  • CC0000: The color(s) red and black is/are claimed as a feature of the mark.
  • GS0441: Telemedicine services; health care; convalescent home services; physical therapy services; health counseling; pharmacy advice, namely, pharmaceutical advice
  • GS0421: Research and development of new products for others; technological research in the field of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical research; conducting clinical trials for others for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biological research; quality control for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; electronic data storage; material testing; cloud computing featuring software for use in database management, word processing, spreadsheet management, tracking; packaging design
Case File Event Statements
  • 3/24/2023 - a year ago
    39 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 3/24/2023 - a year ago
    38 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 3/24/2023 - a year ago
    37 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 12/8/2022 - a year ago
    36 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN
  • 12/8/2022 - a year ago
    35 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 12/8/2022 - a year ago
    34 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 12/8/2022 - a year ago
    33 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 12/8/2022 - a year ago
    32 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR
  • 9/27/2022 - 2 years ago
    31 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC
  • 9/27/2022 - 2 years ago
    30 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 8/23/2022 - 2 years ago
    29 - NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Type: SUNA
  • 8/22/2022 - 2 years ago
    28 - ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Type: CNPR
  • 8/19/2022 - 2 years ago
    27 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 8/18/2022 - 2 years ago
    26 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 8/18/2022 - 2 years ago
    25 - TEAS REQUEST FOR RECONSIDERATION RECEIVED Type: ERFR
  • 8/11/2022 - 2 years ago
    24 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN
  • 8/11/2022 - 2 years ago
    23 - FINAL REFUSAL E-MAILED Type: GNFR
  • 8/11/2022 - 2 years ago
    22 - SU - FINAL REFUSAL - WRITTEN Type: CNFR
  • 7/12/2022 - 2 years ago
    21 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 7/12/2022 - 2 years ago
    20 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 7/11/2022 - 2 years ago
    19 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 7/7/2022 - 2 years ago
    18 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 7/7/2022 - 2 years ago
    17 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 7/7/2022 - 2 years ago
    16 - SU - NON-FINAL ACTION - WRITTEN Type: CNRT
  • 6/1/2022 - 2 years ago
    15 - DATA MODIFICATION COMPLETED Type: DMCC
  • 6/1/2022 - 2 years ago
    14 - ASSIGNED TO LIE Type: ALIE
  • 5/26/2022 - 2 years ago
    13 - STATEMENT OF USE PROCESSING COMPLETE Type: SUPC
  • 5/12/2022 - 2 years ago
    12 - USE AMENDMENT FILED Type: IUAF
  • 5/26/2022 - 2 years ago
    11 - CASE ASSIGNED TO INTENT TO USE PARALEGAL Type: AITU
  • 5/12/2022 - 2 years ago
    10 - TEAS STATEMENT OF USE RECEIVED Type: EISU
  • 12/14/2021 - 2 years ago
    9 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 10/19/2021 - 3 years ago
    8 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 10/19/2021 - 3 years ago
    7 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 9/29/2021 - 3 years ago
    6 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 9/13/2021 - 3 years ago
    5 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 9/8/2021 - 3 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 7/23/2021 - 3 years ago
    3 - NOTICE OF DESIGN SEARCH CODE E-MAILED Type: MDSC
  • 7/22/2021 - 3 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 4/19/2021 - 3 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP